IQVIA experts explore the ongoing impact of COVID-19 on European pharmaceutical markets, including unique insights from HCPs on the prescription of newly launched products as well as a renewed focus on the continued impact of COVID-19 on cancer care, with new learnings from IQVIA’s Oncology Dynamics Team.

• COVID-19’s impact on HCP’s intent-to-prescribe newly launched pharmaceutical products
• Oncology patient care in times of COVID-19 – a comparative analysis pre-pandemic vs. present
• How HCP engagement patterns changed during the pandemic

IQVIA Speakers:

Sarah Rickwood, VP, European Thought Leadership & Marketing

Caroline Anger, Associate Director, Global Oncology Offering Development

Dr Nicole Friedersdorf, Global Oncology Associate Product & Strategy Director.